104 related articles for article (PubMed ID: 25151776)
21. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
22. Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization.
Yang XJ; Zhou M; Hes O; Shen S; Li R; Lopez J; Shah RB; Yang Y; Chuang ST; Lin F; Tretiakova MM; Kort EJ; Teh BT
Am J Surg Pathol; 2008 Feb; 32(2):177-87. PubMed ID: 18223319
[TBL] [Abstract][Full Text] [Related]
23. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
24. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
25. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.
Zhou M; Roma A; Magi-Galluzzi C
Clin Lab Med; 2005 Jun; 25(2):247-57. PubMed ID: 15848735
[TBL] [Abstract][Full Text] [Related]
26. A case of oncocytic papillary renal cell carcinoma.
Okada A; Sasaki S; Fujiyoshi Y; Niimi K; Kurokawa S; Umemoto Y; Kohri K
Int J Urol; 2009 Sep; 16(9):765-7. PubMed ID: 19769658
[TBL] [Abstract][Full Text] [Related]
27. Vinculin: its possible use as a marker of normal collecting ducts and renal neoplasms with collecting duct system phenotype.
Kuroda N; Naruse K; Miyazaki E; Hayashi Y; Yoshikawa C; Ashida S; Moriki T; Yamasaki Y; Numoto S; Yamamoto Y; Yamasaki I; Hiroi M; Shuin T; Enzan H
Mod Pathol; 2000 Oct; 13(10):1109-14. PubMed ID: 11048805
[TBL] [Abstract][Full Text] [Related]
28. Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma.
Zhou H; Zheng S; Truong LD; Ro JY; Ayala AG; Shen SS
Hum Pathol; 2014 Jan; 45(1):59-64. PubMed ID: 24182559
[TBL] [Abstract][Full Text] [Related]
29. Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
Wang KL; Weinrach DM; Luan C; Han M; Lin F; Teh BT; Yang XJ
Hum Pathol; 2007 Feb; 38(2):239-46. PubMed ID: 17056094
[TBL] [Abstract][Full Text] [Related]
30. Emerging Entities in Renal Neoplasia.
Mehra R; Smith SC; Divatia M; Amin MB
Surg Pathol Clin; 2015 Dec; 8(4):623-56. PubMed ID: 26612218
[TBL] [Abstract][Full Text] [Related]
31. Histological features of hypovascular or avascular renal cell carcinoma: the experience at four university hospitals.
Onishi T; Oishi Y; Goto H; Yanada S; Abe K
Int J Clin Oncol; 2002 Jun; 7(3):159-64. PubMed ID: 12109517
[TBL] [Abstract][Full Text] [Related]
32. Panel of candidate biomarkers for renal cell carcinoma.
Kim DS; Choi YP; Kang S; Gao MQ; Kim B; Park HR; Choi YD; Lim JB; Na HJ; Kim HK; Nam YP; Moon MH; Yun HR; Lee DH; Park WM; Cho NH
J Proteome Res; 2010 Jul; 9(7):3710-9. PubMed ID: 20455597
[TBL] [Abstract][Full Text] [Related]
33. Composite distal nephron-derived renal cell carcinoma with chromophobe and collecting duct carcinomatous elements.
Kawano N; Inayama Y; Nakaigawa N; Yao M; Ogawa T; Aoki I; Kitamura H; Nakatani Y; Nagashima Y
Pathol Int; 2005 Jun; 55(6):360-5. PubMed ID: 15943794
[TBL] [Abstract][Full Text] [Related]
34. Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma.
Yusenko MV; Kovacs G
Histopathology; 2009 Dec; 55(6):687-95. PubMed ID: 20002769
[TBL] [Abstract][Full Text] [Related]
35. Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma.
Adley BP; Gupta A; Lin F; Luan C; Teh BT; Yang XJ
Am J Clin Pathol; 2006 Jul; 126(1):79-85. PubMed ID: 16753598
[TBL] [Abstract][Full Text] [Related]
36. Renal cancer: cytogenetic and molecular genetic aspects.
Meloni-Ehrig AM
Am J Med Genet; 2002 Oct; 115(3):164-72. PubMed ID: 12407697
[TBL] [Abstract][Full Text] [Related]
37. The distinction of clear cell carcinoma of the female genital tract, clear cell renal cell carcinoma, and translocation-associated renal cell carcinoma: an immunohistochemical study using tissue microarray.
He H; Zhou GX; Zhou M; Chen L
Int J Gynecol Pathol; 2011 Sep; 30(5):425-30. PubMed ID: 21804394
[TBL] [Abstract][Full Text] [Related]
38. Advances in renal neoplasia: recommendations from the 2012 International Society of Urological Pathology Consensus Conference.
Delahunt B; Srigley JR; Montironi R; Egevad L
Urology; 2014 May; 83(5):969-74. PubMed ID: 24661331
[TBL] [Abstract][Full Text] [Related]
39. Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification.
Udager AM; Mehra R
Arch Pathol Lab Med; 2016 Oct; 140(10):1026-37. PubMed ID: 27684973
[TBL] [Abstract][Full Text] [Related]
40. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?
Ng KL; Rajandram R; Morais C; Yap NY; Samaratunga H; Gobe GC; Wood ST
J Clin Pathol; 2014 Feb; 67(2):97-104. PubMed ID: 24170213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
